GlobalData on MSN4mon
Oncoinvent doses first subject in Phase II ovarian cancer treatment trial
Oncoinvent has dosed the first subject in the Phase II clinical trial of Radspherin, an alpha-radiation therapy, for the ...
di1d
Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients
Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in ...